Welcome to our dedicated page for Klotho Neurosciences news (Ticker: KLTO), a resource for investors and traders seeking the latest updates and insights on Klotho Neurosciences stock.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics and biotechnology company whose news flow centers on the development of Klotho gene-based cell and gene therapies for neurodegenerative and age-related disorders. Company announcements describe programs built around a protein derived from a patented form of the human “anti-aging” Klotho gene (s-KL), with a focus on conditions such as ALS, Alzheimer’s disease, and Parkinson’s disease, as well as broader longevity-related indications.
News items for KLTO commonly cover pipeline progress, including manufacturing and development updates for gene therapy candidates like KLTO-101 and KLTO-202, and regulatory milestones such as Orphan Drug Designation for KLTO-202 for the treatment of ALS. Releases also highlight strategic partnerships, notably Klotho’s collaboration with AAVnerGene Inc. to use AAVone and ATHENA platforms for AAV-based manufacturing and tissue-targeted delivery of Klotho gene therapies.
Investors following KLTO news will also see corporate and financing developments, including capital raises, preferred stock transactions described in the company’s S-1 registration statement, and Nasdaq listing and compliance updates. Strategic updates outline Klotho’s efforts to expand beyond neurology into technologies that support healthy brain function, organ health, muscle strength, bone health, and other longevity indicators, as well as its evaluation of complementary longevity-related assets.
Coverage further includes conference participation and scientific engagement, such as presentations at biotech and longevity-focused events and the Inaugural Klotho Conference & Scientific Seminar, where advisors and inventors discuss Klotho gene therapy research. For readers interested in KLTO, this news page aggregates these disclosures so they can review pipeline milestones, partnership announcements, regulatory updates, and strategic communications in one place.
Klotho Neurosciences (NASDAQ:KLTO) is developing two genomics-based diagnostics for longevity research, including a quantitative DNA methylation assay of the alpha-Klotho gene and a multi-gene "Klotho Clock" combining DNA and mRNA analysis.
The company named Dr. Bret Barnes to lead the program and expects a prototype assay in 2026, aiming to use tests in clinical trial stratification and as a revenue-generating service while building a longitudinal database for AI-driven clock improvements.
Klotho Neurosciences (Nasdaq: KLTO) announced that IP Australia has notified the company and its licensor, Universitat Autonoma de Barcelona, that 18 patent claims for composition and use of the human secreted Klotho protein (s-KL) isoform are to be granted.
The claims cover a muscle-cell specific promoter linked to an s-KL gene sequence for treating motor impairment, plus neuronal/iPSC cell uses and delivery systems including AAV and non-viral vectors with muscle or motor neuron tropism.
Klotho Neurosciences (NASDAQ: KLTO) announced that CEO Dr. Joseph Sinkule will present at the Biotech Showcase 2026 in San Francisco on January 13, 2026 at 11:30 AM PT. The event runs January 12–14, 2026 at the Hilton San Francisco Union Square. Company management will be available for one-on-one investor and partner meetings; meeting requests can be sent to ir@klothoneurosciences.com.
Klotho Neurosciences (NASDAQ: KLTO) was named winner of the 2025 BioTech Breakthrough Award for Cell Therapy Innovation of the Year on November 7, 2025. The company was recognized for its work developing gene and cell therapies using a patented secreted form of the human Klotho gene (s-KL) targeting neurodegenerative and age-related diseases including ALS, Alzheimer’s, and Parkinson’s.
The award highlights Klotho’s focus on therapies that aim to address neuronal aging and deliver durable, disease-modifying benefits.
Klotho Neurosciences (Nasdaq: KLTO) said company leaders, including CEO Dr. Joseph Sinkule, will attend Longevity Biotech 2025 in Boston on October 22–23, 2025. The conference at Wightman Mansion (43 Hawes Street, Brookline/Fenway) brings together biotech, pharma, academia and venture participants to discuss longevity therapeutics.
The company will be available for one-on-one meetings with investors and potential partners; meeting requests should be sent to ir@klothoneurosciences.com. Management emphasized focus on disciplined execution and building collaborations to advance therapeutic programs.
Klotho Neurosciences (Nasdaq: KLTO) announced on October 7, 2025 that its Letter of Intent with Turn Biotechnologies was allowed to expire after evaluation by Klotho's board. The board concluded the proposed transaction did not match the company's long-term strategic plan. Klotho will instead concentrate resources on advancing its Klotho anti-aging protein research pipeline and developing treatments targeting longevity.
The company cited the growing longevity medicine market and aging demographics as rationale for prioritizing its human Klotho protein programs.
Klotho Neurosciences (NASDAQ:KLTO) has signed a Letter of Intent to acquire key assets from Turn Biotechnologies in a cash and stock transaction. The deal includes Turn's ERA platform and eTurna RNA delivery system, along with a significant $300 million partnership with a leading South Korean pharmaceutical company.
The acquisition would bring Turn's cellular reprogramming technology, which uses six RNA molecules including Yamanaka factors, together with Klotho's anti-aging expertise. The combined technologies target multiple therapeutic areas including dermatology, ophthalmology, immunology, osteoarthritis, muscle health, and ALS. Post-acquisition, Klotho plans to rebrand and integrate key Turn Biotechnologies team members.
Klotho Neurosciences (NASDAQ: KLTO), a biotechnology company focused on Klotho-based therapeutics for neurodegenerative diseases, announced its CEO Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar. The event will be held at UC-Irvine Beal Applied Innovation Center from September 15-16, 2025.
The company's scientific advisors, Dr. Miguel Chillon and Dr. Assumpcio Bosch, will present their research on Klotho gene therapy for treating ALS, Alzheimer's and longevity. Investors and potential partners interested in meeting with Dr. Sinkule during the conference can contact ir@klothoneuro.com.
Klotho Neurosciences (NASDAQ: KLTO) provided a strategic update highlighting significant milestones in their development of Klotho-based therapeutics for neurodegenerative diseases. The company is targeting an $8 billion market opportunity across ALS, Alzheimer's, and Parkinson's disease treatments.
Key achievements include receiving FDA Orphan Drug Designation for KLTO-202 for ALS treatment, establishing a manufacturing partnership with AAVnerGene, launching a research center in Okinawa, and securing $11 million in financing. The company has also regained Nasdaq compliance and retained full rights to its Klotho programs following the termination of its SkyBell collaboration.
Klotho Neurosciences (NASDAQ:KLTO) has signed a binding agreement to manufacture its KLTO-202 gene therapy candidate using AAVnerGene's platform technology. The collaboration leverages AAVnerGene's innovative 'AAVone' platform and engineered HEK293 cell line for enhanced gene therapy production.
The partnership aims to deliver several key advantages over traditional triple transfection methods, including higher titer concentration, fewer impurities, faster optimization, and reduced costs. Additionally, AAVnerGene's 'ATHENA' platform technology offers specific tissue-targeting capabilities, potentially providing safer alternatives to conventional AAV vectors that typically target the liver.